Form 4: Director Stephen Lockhart Receives WST Stock Grant

West Pharmaceutical Services Director Stephen H. Lockhart acquired 791 shares of common stock via a restricted stock unit grant.

Summary

• Director Stephen H. Lockhart was granted 791 restricted stock units (RSUs) on May 4, 2026.
• The shares were acquired at a price of $0 per share as part of an equity compensation arrangement.
• Following this transaction, the director's total beneficial ownership in West Pharmaceutical Services stands at 3,523.2615 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• The grant aligns the director's interests with those of shareholders through equity ownership.

Negatives

• None identified.

Risks

• The value of the equity grant is subject to market fluctuations in West Pharmaceutical Services' common stock price.

Future Outlook

The restricted stock units are scheduled to vest in full on the date of the next annual shareholder meeting.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure long-term alignment with shareholder interests in the pharmaceutical packaging and delivery systems sector.

Comparison to Industry Standards

• The grant of restricted stock units to directors is consistent with standard compensation practices for S&P 500 and mid-cap healthcare companies.
• The vesting schedule tied to the annual shareholder meeting is a common retention and governance mechanism.

Stakeholder Impact

• Minimal impact on shareholders as the grant represents a standard component of director compensation.

Next Steps

• Vesting of the 791 restricted stock units at the next annual shareholder meeting.

Key Dates

Keywords

West Pharmaceutical Services, WST, Form 4, Insider Trading, Director Compensation, Equity Grant